These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21449914)

  • 1. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10.
    Yoo HD; Lee SN; Kang HA; Cho HY; Lee IK; Lee YB
    Br J Pharmacol; 2011 Sep; 164(2b):433-43. PubMed ID: 21449914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A; Spina E; Dahl ML; Scordo MG
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
    Suzuki Y; Tsuneyama N; Fukui N; Sugai T; Watanabe J; Ono S; Saito M; Someya T
    J Clin Psychopharmacol; 2013 Jun; 33(3):411-4. PubMed ID: 23609388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
    Cho HY; Lee YB
    Arch Pharm Res; 2006 Jun; 29(6):525-33. PubMed ID: 16833023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
    Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.
    Sherwin CM; Saldaña SN; Bies RR; Aman MG; Vinks AA
    Ther Drug Monit; 2012 Oct; 34(5):535-44. PubMed ID: 22929407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.
    Mas S; Gassò P; Alvarez S; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2012 Jun; 12(3):255-9. PubMed ID: 21173786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A; Piotrovsky V; Ludwig EA
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
    Kneller LA; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.
    Berecz R; LLerena A; de la Rubia A; Gómez J; Kellermann M; Dorado P; Degrell I
    Pharmacopsychiatry; 2002 Nov; 35(6):231-4. PubMed ID: 12518271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants.
    Schoretsanitis G; de Leon J; Diaz FJ
    Pharmacogenomics; 2018 Jul; 19(10):815-823. PubMed ID: 29914302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.